Abstract.
β-Glucan primes leukocyte CR3 for enhanced cytotoxicity and synergizes with anti-tumor monoclonal antibodies (mAb). We studied readily available (1→3)-β-D-glucan using the immune deficient xenograft tumor models, and examined the relationship of its anti-tumor effect and physico-chemical properties. Established subcutaneous (s.c.) human xenografts were treated for 29 days orally with daily β-glucan by intragastric injection and mAb intravenously (i.v.) twice weekly. Control mice received either mAb alone or β-glucan alone. Tumor sizes were monitored over time. β-Glucans were studied by carbohydrate linkage analysis, and high performance size-exclusion chromatography with multiple angle laser scattering detection. Orally administered β-D-glucan greatly enhanced the anti-tumor effects of mAb against established tumors in mice. We observed this β-glucan effect irrespective of antigen (GD2, GD3, CD20, epidermal growth factor-receptor, HER-2), human tumor type (neuroblastoma, melanoma, lymphoma, epidermoid carcinoma and breast carcinoma) or tumor sites (s.c. versus systemic). This effect correlated with the molecular size of the (1→3),(1→4)-β-D-glucan. Orally administered (1→3),(1→6)-β-D-glucans also synergized with mAb, although the effect was generally less marked. Given the favorable efficacy and toxicity profile of oral β-D-glucan treatment, the role of natural products that contain β-glucan in cancer treatment as an enhancer of the effect of mAb therapy deserves further study.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Electronic Publication
Rights and permissions
About this article
Cite this article
Cheung, NK.V., Modak, S., Vickers, A. et al. Orally administered β-glucans enhance anti-tumor effects of monoclonal antibodies. Cancer Immunol Immunother 51, 557–564 (2002). https://doi.org/10.1007/s00262-002-0321-3
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s00262-002-0321-3